Cancer risk is a theoretical concern with any growth hormone influencing compound
Nhiu hng sn xut iu ch glutathione dng vin hoc dng nc ung v nhn c rt nhiu phn hi tt
Scandinavian J Immunol (1994) 40:6018
Primary endpoint is time to first occurrence of any of the adjudicated components of a 5P-MACE composite consisting of: CV death, non-fatal stroke, non-fatal MI, ischaemia-related coronary revascularisation, or HF event (including hospitalisation for HF, emergency department, urgent care, or urgent outpatient HF visit)
[10] [11] Additional safety considerations include caution in patients with severe gastroparesis, gallbladder disease, and a potential risk of diabetic retinopathy complications with rapid glucose improvement (particularly with semaglutide)